First Clinical Use of Aztreonam-Avibactam for Treating Resistant Infections
Author Information
Author(s): Hölsken Oliver, Sponheuer Keno, Weber Franz, Martens-Lobenhoffer Jens, Bode-Böger Stefanie M., Kloft Charlotte, Treskatsch Sascha, Angermair Stefan
Primary Institution: Charité—Universitätsmedizin Berlin
Hypothesis
Can population pharmacokinetic models accurately predict in vivo concentrations of aztreonam-avibactam in a critically ill patient?
Conclusion
Population pharmacokinetic models for aztreonam-avibactam accurately predicted in vivo concentrations in a severely ill patient with hospital-acquired pneumonia.
Supporting Evidence
- The patient showed clinical improvement and sterile blood cultures within 12 days.
- Median aztreonam concentrations remained above the minimum inhibitory concentration for the pathogen.
- Bland-Altman analysis demonstrated reasonable agreement between predicted and observed concentrations.
Takeaway
Doctors used a new medicine called aztreonam-avibactam to help a very sick patient with a tough infection, and it worked well.
Methodology
The study involved therapeutic drug monitoring and population pharmacokinetic modeling to assess drug concentrations in a patient treated with aztreonam-avibactam.
Potential Biases
Potential bias due to the retrospective nature of the study and reliance on a single patient case.
Limitations
The study is limited by the small sample size of a single patient, which restricts the generalizability of the findings.
Participant Demographics
{"age":70,"sex":"male","height_cm":185,"weight_kg":151,"BMI":45,"APACHE_II_score":19,"primary_diagnosis":"hospital-acquired pneumonia","co_morbidities":["heart failure","obstructive sleep apnea","diabetes mellitus"]}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website